EW

SEC source: 0001225208-17-010120 · doc4.xml · nonDerivative · entry 1

Verguet Patrick B · CIK 0001308771 · CVP, Europe

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,768.1496

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.

SEC source: 0001225208-17-009815 · doc4.xml · nonDerivative · entry 4

Verguet Patrick B · CIK 0001308771 · CVP, Europe

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,768.1496

F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.

SEC source: 0001225208-17-009815 · doc4.xml · nonDerivative · entry 3

Verguet Patrick B · CIK 0001308771 · CVP, Europe

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,368.1496

F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.

SEC source: 0001225208-17-009993 · doc4.xml · nonDerivative · entry 1

SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,852.3757

F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009815 · doc4.xml · derivative · entry 5

Verguet Patrick B · CIK 0001308771 · CVP, Europe

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,800

Underlying: Common Stock · 7,000 shares

Expires 2018-05-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.

SEC source: 0001225208-17-009815 · doc4.xml · nonDerivative · entry 2

Verguet Patrick B · CIK 0001308771 · CVP, Europe

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,268.1496

F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.

SEC source: 0001225208-17-009815 · doc4.xml · nonDerivative · entry 1

Verguet Patrick B · CIK 0001308771 · CVP, Europe

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,268.1496

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.

SEC source: 0001225208-17-009793 · doc4.xml · nonDerivative · entry 1

VALERIANI NICHOLAS J · CIK 0001263149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,017

F1 · shares: These restricted stock units were granted on May 12, 2017 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009791 · doc4.xml · nonDerivative · entry 2

VON SCHACK WESLEY W · CIK 0001025355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,622

F3 · shares: This restricted stock was granted on May 12, 2017 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person; and it includes 2,524 shares previously reported as directly held.

SEC source: 0001225208-17-009791 · doc4.xml · nonDerivative · entry 1

VON SCHACK WESLEY W · CIK 0001025355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,034

F1 · shares: These restricted stock units were granted on May 12, 2017 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person; and it includes 2,524 shares previously reported as directly held.

SEC source: 0001225208-17-009788 · doc4.xml · nonDerivative · entry 1

Marsh Martha H. · CIK 0001500281 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,975

F1 · shares: These restricted stock units were granted on May 12, 2017 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009787 · doc4.xml · nonDerivative · entry 2

LORANGER STEVEN R · CIK 0001226924 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,563

F3 · shares: This restricted stock was granted on May 12, 2017 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009787 · doc4.xml · nonDerivative · entry 1

LORANGER STEVEN R · CIK 0001226924 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,975

F1 · shares: These restricted stock units were granted on May 12, 2017 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009786 · doc4.xml · nonDerivative · entry 2

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,596

F3 · shares: This restricted stock was granted on May 12, 2017 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and is scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009786 · doc4.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,008

F1 · shares: These restricted stock units were granted on May 12, 2017 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009785 · doc4.xml · derivative · entry 2

STONE HEISZ LESLIE · CIK 0001235408 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,352

Underlying: Common Stock · 2,352 shares

Expires 2024-05-11

F3 · derivative.exercise_date: These options were granted on May 12, 2017 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and became fully exercisable on the grant date.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009785 · doc4.xml · nonDerivative · entry 1

STONE HEISZ LESLIE · CIK 0001235408 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,034

F1 · shares: These restricted stock units were granted on May 12, 2017 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009784 · doc4.xml · derivative · entry 3

GALLAHUE KIERAN · CIK 0001308428 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,352

Underlying: Common Stock · 2,352 shares

Expires 2024-05-11

F3 · derivative.exercise_date: These options were granted on May 12, 2017 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and became fully exercisable on the grant date.

F4 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009784 · doc4.xml · nonDerivative · entry 1

GALLAHUE KIERAN · CIK 0001308428 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,034

F1 · shares: These restricted stock units were granted on May 12, 2017 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person; and it reflects 2,524 shares that were previously reported as directly held.

SEC source: 0001225208-17-009795 · doc4.xml · derivative · entry 4

Wood Larry L · CIK 0001440660 · CVP, THV Replacement

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,625

Underlying: Common Stock · 3,625 shares

Expires not disclosed

F5 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F5 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F5 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F5 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F5 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.

SEC source: 0001225208-17-009795 · doc4.xml · derivative · entry 3

Wood Larry L · CIK 0001440660 · CVP, THV Replacement

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,600

Underlying: Common Stock · 25,600 shares

Expires 2024-05-10

F4 · derivative.exercise_date: These options were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.

SEC source: 0001225208-17-009795 · doc4.xml · nonDerivative · entry 1

Wood Larry L · CIK 0001440660 · CVP, THV Replacement

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,372.6731

F1 · shares: These restricted stock units were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.

SEC source: 0001225208-17-009783 · doc4.xml · derivative · entry 2

SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,070

Underlying: Common Stock · 4,070 shares

Expires 2024-05-10

F3 · derivative.exercise_date: These options were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009783 · doc4.xml · nonDerivative · entry 1

SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,174.3757

F1 · shares: These restricted stock units were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009781 · doc4.xml · derivative · entry 3

WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,875

Underlying: Common Stock · 1,875 shares

Expires not disclosed

F4 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F4 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F4 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F4 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F4 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.

SEC source: 0001225208-17-009781 · doc4.xml · derivative · entry 2

WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,700

Underlying: Common Stock · 14,700 shares

Expires 2024-05-10

F3 · derivative.exercise_date: These options were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 equal monthly installments.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.

SEC source: 0001225208-17-009781 · doc4.xml · nonDerivative · entry 1

WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,991.0375

F1 · shares: These restricted stock units were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.

SEC source: 0001225208-17-009779 · doc4.xml · derivative · entry 5

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,975

Underlying: Common Stock · 14,975 shares

Expires not disclosed

F5 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F5 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F5 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F5 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F5 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.

SEC source: 0001225208-17-009779 · doc4.xml · derivative · entry 4

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,400

Underlying: Common Stock · 117,400 shares

Expires 2024-05-10

F4 · derivative.exercise_date: These options were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 equal monthly installments.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.

SEC source: 0001225208-17-009779 · doc4.xml · nonDerivative · entry 1

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,130.82

F1 · shares: These restricted stock units were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.

SEC source: 0001225208-17-009778 · doc4.xml · derivative · entry 5

BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,625

Underlying: Common Stock · 3,625 shares

Expires not disclosed

F5 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F5 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F5 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F5 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F5 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009778 · doc4.xml · derivative · entry 4

BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,500

Underlying: Common Stock · 28,500 shares

Expires 2024-05-10

F4 · derivative.exercise_date: These options were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 equal monthly installments.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009778 · doc4.xml · nonDerivative · entry 1

BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,182.6555

F1 · shares: These restricted stock units were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009777 · doc4.xml · derivative · entry 3

Zovighian Bernard J · CIK 0001665141 · CVP, Surgical Heart Valves

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,175

Underlying: Common Stock · 3,175 shares

Expires not disclosed

F4 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F4 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F4 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F4 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F4 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009777 · doc4.xml · derivative · entry 2

Zovighian Bernard J · CIK 0001665141 · CVP, Surgical Heart Valves

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,400

Underlying: Common Stock · 22,400 shares

Expires 2024-05-10

F3 · derivative.exercise_date: These options were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009777 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · CVP, Surgical Heart Valves

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,102.4816

F1 · shares: These restricted stock units were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009774 · doc4.xml · derivative · entry 4

Ullem Scott B. · CIK 0001446989 · CVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,775

Underlying: Common Stock · 3,775 shares

Expires not disclosed

F4 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F4 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F4 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F4 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F4 · derivative.underlying: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009774 · doc4.xml · derivative · entry 3

Ullem Scott B. · CIK 0001446989 · CVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,600

Underlying: Common Stock · 26,600 shares

Expires 2024-05-10

F3 · derivative.exercise_date: These options were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009774 · doc4.xml · nonDerivative · entry 1

Ullem Scott B. · CIK 0001446989 · CVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,234

F1 · shares: These restricted stock units were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009772 · doc4.xml · derivative · entry 4

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,400

Underlying: Common Stock · 3,400 shares

Expires not disclosed

F5 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F5 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F5 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F5 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F5 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F4 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009772 · doc4.xml · derivative · entry 3

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2024-05-10

F3 · derivative.exercise_date: These options were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

F4 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009772 · doc4.xml · nonDerivative · entry 1

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,528.1453

F1 · shares: These restricted stock units were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator.

SEC source: 0001225208-17-009635 · doc4.xml · derivative · entry 4

Wood Larry L · CIK 0001440660 · CVP, THV Replacement

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,500 shares

Expires 2017-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.

F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.

F1 · price: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.

F1 · derivative.exercise_date: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.

F1 · derivative.underlying_shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.

F4 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009635 · doc4.xml · nonDerivative · entry 2

Wood Larry L · CIK 0001440660 · CVP, THV Replacement

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,472.6731

F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator.

SEC source: 0001225208-17-009635 · doc4.xml · nonDerivative · entry 1

Wood Larry L · CIK 0001440660 · CVP, THV Replacement

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,626.6731

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.

F1 · price: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator.

SEC source: 0001225208-17-009633 · doc4.xml · derivative · entry 4

Ullem Scott B. · CIK 0001446989 · CVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,500 shares

Expires 2017-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.

F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.

F1 · price: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.

F1 · derivative.exercise_date: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.

F1 · derivative.underlying_shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009633 · doc4.xml · nonDerivative · entry 2

Ullem Scott B. · CIK 0001446989 · CVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,230

F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009633 · doc4.xml · nonDerivative · entry 1

Ullem Scott B. · CIK 0001446989 · CVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,709

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.

F1 · price: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009632 · doc4.xml · derivative · entry 5

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 44,275 shares

Expires 2017-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 8, 2014, the Reporting Person was granted a target number of shares (25,300) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.

F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (25,300) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.

F1 · price: On May 8, 2014, the Reporting Person was granted a target number of shares (25,300) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.

F1 · derivative.exercise_date: On May 8, 2014, the Reporting Person was granted a target number of shares (25,300) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.

F1 · derivative.underlying_shares: On May 8, 2014, the Reporting Person was granted a target number of shares (25,300) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009632 · doc4.xml · nonDerivative · entry 2

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,155.82

F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (25,300) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.